Focusing on NF-κB presents promising therapeutic opportunities, such as developing specific NF-κB inhibitors, integrating therapies with chemotherapy and immunotherapy, and developing personalized treatment approaches based on tumor-specific biomarkers. Here, NFKB1 is linked to neoplasm.